Amy Buck
Family · O Fallon, ILNPI 1053587402
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $17,064 of the $26,385 with a category attached, or 64.7%. Axsome Therapeutics, Inc. accounts for 76.1% of it on its own, with 24 other manufacturers making up the rest. 2025 is the largest year on record at $22,346, more than ten times the $1,227 reported in 2021. Among family clinicians in IL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 517 payments — averaging $51.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Axsome Therapeutics, Inc.$20K
- Novo Nordisk$1K
- AbbVie$1K
- AstraZeneca$757
- Lilly USA, LLC$447
- Lundbeck LLC$323
- plus $2K from 19 others
What the payments were for
- Speaking & faculty fees$17,06465%
- Travel & lodging$1,8227%
- Food & beverage$7,49928%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Axsome Therapeutics, Inc. | 49 | $20,092 |
| Novo Nordisk | 126 | $1,465 |
| AbbVie | 125 | $1,401 |
| AstraZeneca | 29 | $757 |
| Lilly USA, LLC | 34 | $447 |
| Lundbeck LLC | 26 | $323 |
| Pfizer | 39 | $303 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 12 | $254 |
| Boehringer Ingelheim | 15 | $244 |
| Otsuka America Pharmaceutical, Inc. | 13 | $239 |
| Takeda Pharmaceuticals U.S.A., Inc. | 10 | $180 |
| Ironshore Pharmaceuticals Inc. | 5 | $112 |
| Amgen | 7 | $108 |
| Johnson & Johnson | 6 | $105 |
| Biohaven Pharmaceuticals, Inc. | 3 | $60 |
| Supernus Pharmaceuticals, Inc. | 4 | $58 |
| Tris Pharma Inc | 3 | $58 |
| Exact Sciences | 3 | $46 |
| Cranial Technologies, Inc | 2 | $28 |
| Amarin Pharma, Inc. | 1 | $23 |
| Abbott | 1 | $21 |
| Sanofi Pasteur Inc. | 1 | $18 |
| GSK | 1 | $16 |
| Collegium Pharmaceutical, Inc. | 1 | $14 |
| Bayer | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$26,385 in reported general payments places this provider in the 95th percentile of 4,941 family providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 58 | $77,604 |
| ForteoTeriparatide | 12 | $60,520 |
| VraylarCariprazine Hcl | 17 | $41,515 |
| FarxigaDapagliflozin Propanediol | 34 | $39,005 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 32 | $30,233 |
| AuvelityDextromethorphan Hbr/Bupropion | 14 | $21,707 |
| TrulicityDulaglutide | 17 | $21,220 |
| MounjaroTirzepatide | 19 | $19,916 |
| EliquisApixaban | 23 | $18,869 |
| Xigduo XrDapaglifloz Propaned/Metformin | 16 | $16,096 |
| Tresiba Flextouch U-200Insulin Degludec | 19 | $13,454 |
| LinzessLinaclotide | 13 | $12,038 |
| Aimovig AutoinjectorErenumab-Aooe | 12 | $8,307 |
| Breo ElliptaFluticasone/Vilanterol | 12 | $5,169 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 55 | $2,705 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCForteo, Trulicity, Mounjaro | $447 | $101,65648 claims |
| Novo NordiskOzempic | $1,465 | $77,60458 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $757 | $69,23866 claims |
| AbbVieVraylar, Linzess, Synthroid | $1,401 | $54,24047 claims |
| Axsome Therapeutics, Inc.Auvelity | $20,092 | $21,70714 claims |
| PfizerEliquis | $303 | $18,86923 claims |
| GSKBreo Ellipta | $16 | $5,16912 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,941 family providers in Illinois.
Other family in O Fallon
- Jennifer MartensO Fallon$159K
- Ruth CarricoChicago$578K
- Aleksandra BielawiecBarrington$373K
- Erin SieberNaperville$334K
- Jamie BroganChicago$282K
- Ashley NoethGlen Carbon$271K
- Marita KametasChicago$259K
- Shammona ClarkChicago$247K
- Amanda McKeeMount Vernon$242K
- Amy BrownellElk Grove Village$202K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.